Chlorpyrifos has undergone dramatic changes in its market trajectory, from a blockbuster proprietary molecule to a globally traded generic active ingredient. AgriBusiness Global spoke with Ram ...

In 2026, Novo Nordisk’s patent on semaglutide will expire in several countries, including India and China. Generic-drug makers are poised to flood these markets with inexpensive products. Industry ...

Jamie Dimon is right to be alarmed about our national-security vulnerabilities, especially an overreliance on China and India for generic prescription drugs (“Investments for National Security,” op-ed ...

Entresto generics have finally arrived in the U.S. in July, and approximately 9% of Novartis' revenue will be impacted. The growth of other key products and of Entresto in ex-U.S. territories should ...

This annual observance highlights the importance of generic medicines in providing affordable, effective and accessible healthcare to Filipinos. It was held under the theme “Ginhawang Generics, Ramdam ...

Generic drugs are cheaper copies of brand drugs, offering significant savings to patients. Once a brand-name drug's patent expires, competitors can apply to make generic versions. Generic ...

ANDERLECHT, Belgium--(BUSINESS WIRE)--A.forall is pleased to announce the acquisition of four FDA-approved injectable generics and two late-stage pipeline assets from Provepharm's US portfolio. With ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. For the first time, a generic GLP-1 has been approved by ...

Generics distribution and telemedicine startup Truemeds aims to bridge the accessibility gap in a market known for low-cost generics, but ruled by expensive branded drugs By cutting out marketing and ...

Forbes contributors publish independent expert analyses and insights. Sally Pipes is a scholar and think tank CEO who writes on health care. America’s generic drug market is one of our greatest health ...

Sun Pharmaceutical and its Taro Pharmaceutical subsidiary are washing their hands of another segment of a years-long antitrust debacle with a $200 million settlement. The deal will clear all claims ...